Ethambutol (dihydrochloride)

1070-11-7

C10H26Cl2N2O2

DMSO : 100 mg/mL (360.71 mM; Need ultrasonic); H2O : >= 50 mg/mL (180.36 mM)

Anti-infection

Ethambutol dihydrochloride (Emb dihydrochloride) is a bacteriostatic antimycobacterial agent, which obstructs the formation of cell wall by inhibiting arabinosyl transferases. Target: Antibacterial Ethambutol dihydrochloride (Emb dihydrochloride) directly affects two polymers, arabinogalactan (AG) and lipoarabinomannan (LAM) in Mycobacterium smegmatis. In M. smegmatis, Ethambutol inhibits synthesis of arabinan completely and inhibits AG synthesis most likely as a consequence of this; more than 50% of the cell arabinan is released from the bacteria following Ethambutol treatment, whereas no galactan is released. Ethambutol main targets against embB gene product in M. avium. Ethambutol induces 60% changes in the embB gene in M. tuberculosis resistant mutants [1]. Ethambutol dihydrochloride (Emb dihydrochloride) is effective against actively growing microorganisms of the genus Mycobacterium, including M. tuberculosis. Nearly all strains of M. tuberculosis and M. kansasii as well as a number of strains of the M. aviumcomplex (MAC) are sensitive to Ethambutol. [1] Ethambutol dihydrochloride (Emb dihydrochloride) is potency against M. tuberculosis (H37Rv) with MIC of 0.5 ug/mL in vitro [2]. Ethambutol is efficient on treatment of mycobacterial-infected macrophages. When M. tuberculosis infected macrophages are treated with 6 ug/mL Ethambutol, the log CFUs following treatment for 3 days is 4.17, while value in control group is 4.8. The MICs for M. avium (MTCC 1723) and M. smegmatis (MTCC 6) are 15 ug/mL and 0.18 ug/mL, respectively. Ethambutol is efficient in animal model. 100 mg/kg Ethambutol given orally 15 days post i.v. infection 1 x/week for 5 weeks, induces a lower log CFU compared with untreatment (4.59 vs 5.07) [3].